Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission - 31/01/23
Doi : 10.1016/S1470-2045(23)00007-4
Raffaella Casolino a 
, Amber L Johns b, Melanie Courtot c, Rita T Lawlor d, Francesco De Lorenzo e, Denis Horgan f, Joaquin Mateo g, h, Nicola Normanno i, Mark Rubin j, k, Lincoln Stein c, Vivek Subbiah g, l, Benedikt C Westphalen g, n, Mark Lawler o, Keunchil Park m, Sandra Perdomo p, Takayuki Yoshino q, Jianmin Wu r, Andrew V Biankin a, s, t
on behalf of the
, Amber L Johns b, Melanie Courtot c, Rita T Lawlor d, Francesco De Lorenzo e, Denis Horgan f, Joaquin Mateo g, h, Nicola Normanno i, Mark Rubin j, k, Lincoln Stein c, Vivek Subbiah g, l, Benedikt C Westphalen g, n, Mark Lawler o, Keunchil Park m, Sandra Perdomo p, Takayuki Yoshino q, Jianmin Wu r, Andrew V Biankin a, s, ton behalf of the
Lancet Oncology Commission on Cancer Omics and Precision Oncology
a Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, UK
b Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW, Australia
c Ontario Institute for Cancer Research, Toronto, ON, Canada
d ARC-NET Research Centre, University and Hospital Trust of Verona, Verona, Italy
e European Cancer Patient Coalition, Brussels, Belgium
f European Alliance for Personalised Medicine, Brussels, Belgium
g ESMO Translational Research and Precision Medicine Working Group, Lugano, Switzerland
h Medical Oncology, Vall d’Hebron Institute of Oncology, Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
i Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, Naples, Italy
j Department for BioMedical Research, University of Bern, Bern, Switzerland
k Bern Center for Precision Medicine, Inselspital, University Hospital of Bern, Bern, Switzerland
l Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
m Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
n Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich, Munich, Germany
o Patrick G Johnston Centre for Cancer Research, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, UK
p Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
q Department of Gastroenterology and Gastrointestinal Oncology and Division for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Japan
r Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Center for Cancer Bioinformatics, Peking University Cancer Hospital & Institute, Beijing, China
s West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK
t South Western Sydney Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
Le texte complet de cet article est disponible en PDF.
© 2023
Elsevier Ltd. Tous droits réservés.© 2023
Jim Varney/Science Photo Library. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 24 - N° 2
P. 123-125 - février 2023 Retour au numéro
Article précédent
- On a precipice: the UK’s broken health-care system
- David Collingridge
- International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges
- Ben J Slotman, Thomas J Eichler
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?